Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
NCT ID NCT07766772
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This phase 2 trial is testing a two-step treatment approach for people with advanced HER2-positive breast cancer. First, participants receive an induction therapy with trastuzumab rezetecan. If the disease does not progress, they then move to a maintenance phase combining trastuzumab, pyrotinib, and capecitabine, with or without endocrine therapy. The goal is to see if this sequential strategy can extend the time before the cancer worsens, while also checking safety and other response measures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A sequence of drug combinations: trastuzumab rezetecan (induction), then trastuzumab with pyrotinib and capecitabine (maintenance), with optional endocrine therapy.
- What this could lead to
- If successful, this sequential approach could offer a new first-line treatment option that delays disease progression in advanced HER2-positive breast cancer.
- What could go wrong
- This is an early-phase, single-arm study with a small number of participants, so results may not be conclusive. The drug combinations may cause side effects, and the benefit over existing treatments is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hosptial
Fuzhou, Fujian, 350004, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Can an oral chemo pill boost breast cancer treatment?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- New drug sequence aims to outsmart advanced breast cancer